Esophagus Cancer, Adenocarcinoma Clinical Trial
Official title:
Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Adenocarcinomas
The aim of this study is to investigate urokinase Plasminogen Activator Receptor (uPAR) microexpression in gastroesophageal cancer (adenocarcinomas) both qualitatively and semi-quantitatively and to evaluate if it offers a possibility for future imagining purposes.
- Sections of the tumor tissue will be HE stained. - Sections of the tumor tissue will be stained with an uPAR antibody for immunohistochemistry. - Immunohistochemical staining against cytokeratin which colors cancer cells will be made to assist the observer in the evaluation of uPAR microexpression pattern. - A semiqualitative scale corresponding to the level of uPAR expression will be made. - Quantitative polymerase chain reaction will be used to validate the immunohistochemistry uPAR expression pattern. - An electronic scoring system (digital pathology) will be trained to access the expression of uPAR in both tumor- and normal tissue. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05069766 -
Preoperative Marking of the Oral Resection Margin in Esophageal Cancer With a Surgical Fiducial Marker - First Experiences
|
N/A | |
| Active, not recruiting |
NCT03995017 -
Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma
|
Phase 1/Phase 2 |